Capricor Therapeutics, Inc. (CAPR)
Automate Your Wheel Strategy on CAPR
With Tiblio's Option Bot, you can configure your own wheel strategy including CAPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CAPR
- Rev/Share 0.3805
- Book/Share 2.797
- PB 2.7458
- Debt/Equity 0.0098
- CurrentRatio 6.5475
- ROIC -0.4331
- MktCap 351035904.0
- FreeCF/Share -1.0337
- PFCF -7.441
- PE -6.365
- Debt/Assets 0.0081
- DivYield 0
- ROE -0.6242
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CAPR | Roth Capital | -- | Buy | -- | $31 | May 20, 2025 |
| Initiation | CAPR | Piper Sandler | -- | Overweight | -- | $35 | Oct. 21, 2024 |
News
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m.
Read More
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Published: March 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference--
Read More
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
Published: March 10, 2025 by: PRNewsWire
Sentiment: Neutral
PARAMUS, N.J. , March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.
Read More
Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida.
Read More
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
Published: March 04, 2025 by: Benzinga
Sentiment: Positive
On Tuesday, the FDA accepted for review Capricor Therapeutics Inc's CAPR Biologics License Application for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.
Read More
Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data
Published: February 23, 2025 by: Seeking Alpha
Sentiment: Positive
Capricor Therapeutics has filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD cardiomyopathy, with strong FDA recognition. Deramiocel's efficacy was demonstrated in the HOPE-2 trials, with significant improvements in PUL 1.2 scores and positive long-term benefits in PUL 2.0 and LVEF measures. Financially, Capricor is well-positioned with a strong cash runway, strategic partnerships, and projected significant revenue from deramiocel sales by 2030.
Read More
About Capricor Therapeutics, Inc. (CAPR)
- IPO Date 2007-02-13
- Website https://www.capricor.com
- Industry Biotechnology
- CEO Dr. Linda Marbán Ph.D.
- Employees 160